High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study

Journal of Neurology

Volumn 247, Issue 1, 2000, Pages 22-28

  Walter, Maggie C ^a   Lochmüller, Hanns ^a   Toepfer, Marcel ^a   Schlotter, Beate ^a   Reilich, Peter ^a   Schröder, Mira ^a   Müller Felber, Wolfgang ^a   Pongratz, Dieter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunoglobulin therapy; Inflammatory myopathy; Sporadic inclusion body myositis

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROMYOGRAPHY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; MALE; MUSCLE ATROPHY; MUSCLE WEAKNESS; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SYMPTOM;

EID: 0034022024     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050005     Document Type: Article

References (37)

1. 1. Amato AA, Barohn RJ, Jackson CE, et al (1994) Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 44 : 1516-1518
2. 2. Argov Z, Tiram E, Eisenberg I, Sadeh M, Seidman CE, Seidman JG, Karpati G, Mitrani-Rosenbaum S (1997) Various types of hereditary inclusion body myopathies map to chromosome 9p1-q1. Ann Neurol 41 : 548-551
3. 3. Barohn RJ, Amato AA, Sahenk Z, Kissel JR, Mendell JR (1995) Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 45 : 1302-1304
4. 4. Bender A, Behrens L, Engel AG, Hohlfeld R (1998) T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 84 : 86-91
5. 5. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, FatehMoghadam A (1983) Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33 : 1316-1321
6. 6. Bouche P, Moulonguet A, Younes-Chennoufi AB, Adams D, Baumann N, Meininger V, Leger JM, Said G (1995) Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 59 : 38-44
7. 7. Carpenter S, Karpati, G, Heller I, Eisen A (1978) Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 28 : 8-17
8. 8. Cherin P, Herson S, Wechsler B, et al (1991) Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 44 : 1516-1518
9. 9. Chou SM (1967) Myxovirus-like structures in a case of human chronic polymyositis. Science 15 : 1453-1455
10. 10. Chou SM (1993) Inclusion body myositis. Baillieres Clin Neurol 2 : 557-577
11. 11. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 325 : 1487-1498
12. 12. Dalakas MC (1995) Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol [Suppl]6 : 70S-75S
13. 13. Dalakas MC (1996) Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 104 [Suppl]1 : 55-60
14. 14. Dalakas MC, Sonies BC, Lopez-Devine J, Sapper DJ (1996) Dysphagia as a frequent manifestation in patients with inclusion body myositis. Neurology 46 [Suppl] : A116
15. 15. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48 : 712-716
16. 16. Fujii M, Koffman B, Sivakumar K, Dalakas MC (1997) Histologic characteristics in repeated muscle biopsies of patients with inclusion body myositis (IBM) treated in a control trial with high-dose intravenous immunoglobulin (IVIg) and prednisone. Neurology 48 [Suppl 2] : A332-333
17. 17. Fyhr IM, Moslemi AR, Tarkowski A, Lindberg C, Oldfors A (1996) Limited T-cell receptor V gene usage in inclusion body myositis. Scand J Immunol 43 : 109-114
18. 18. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL (1994) HLA associations with inclusion body myositis. Clin Exp Immunol 98 : 40-45
19. 19. Grehl H, Jaspert A, Claus D, Neundorfer B (1997) Long-term therapy with high-dose intravenous immunoglobulins (IVIG) in inflammatory neuropathies. Eur J Neurol 4 : 266-273
20. 20. Hopkinson ND, Hunt C, Powell RJ, Lowe J (1993) Inclusion body myositis: an underdiagnosed condition? Ann Rheum Dis 52 : 147-151
21. 21. Imbach P, Barandun S, Cottier H, Gugler E, Hassig A, More A, Wagner H, Heiniger H (1990) Immunomodulation by intravenous immunoglobulin. Am J Pediatr Hematol Oncol 12 : 134-140
22. 22. Koffman BM, Rugiero M, Dalakas MC (1998) Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21 : 115-117
23. 23. Lindberg C, Oldfors A, Hedstrom A (1990) Inclusion body myositis: periphal nerve involvement. Combined morphological and electrophysiological studies on periphal nerves. J Neurol Sci 99 : 327-338
24. 24. Lindberg C, Persson LI, Björkander J, Olfors A (1994) Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 89 : 123-131
25. 25. Masur H, Papke K, Althoff S, Oberwittler C (1995) Symptomorientierte Skalen und Skores. In: Skalen und Scores in der Neurologie, 1st edn. Thieme, Stuttgart, pp 68-72
26. 26. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E (1997) Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63 : 765-769
27. 27. Milner-Brown HS, Mellenthin M, Sharma ML, Miller RG (1987) Quantiative correlation between plasma pyridostigmin levels and neuromuscular function in myasthenia gravis. Neurology 37 : 800-803
28. 28. Naumann M, Reichmann H, Goebel HH, Moll C, Toyka KV (1996) Glucocorticoid-sensitive hereditary inclusion body myositis. J Neurol 1243 : 126-130
29. 29. Pouget J, Pellissier JF, Serratrice G (1987) Electromyographic aspects of inclusion body myositis. Macro-electromyographic study. Rev Electroencephalogr Neurophysiol Clin 3 : 319-328
30. 30. Sekul EA, Dalakas MC (1993) Inclusion body myositis: new concepts. Semin Neurol 13 : 256-263
31. 31. Serratrice G, Pellissier JF, Pouget J, Figarella-Branger D (1989) Clinical forms of inclusion body myositis: 12 cases. Rev Neurol (Paris) 145 : 781-788
32. 32. Serratrice G (1996) Inclusion body myositis Presse Med 25 : 985-988
33. 33. Soueidan SA, Dalakas MC (1993) Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 43 : 876-879
34. 34. Vershuuren JJ, van Engelen BGM, van der Hoeven H, Hoogendijk J (1997) Diagnostic criteria of inclusion body myositis. In: Emery AEH (ed) Diagnostic criteria for neuromuscular disorders, 2nd edn. Royal Society of Medicine, London, pp 81-85
35. 35. Wolf HM, Eibl MM (1996) Immunomodulatory effect of immunoglobulins. Clin Exp Rheumatol 14 [Suppl]15 : 17-25
36. 36. Yoy JL, Oh SJ, Baysal AI (1990) Electrophysiological spectrum of inclusion body myositis. Muscle Nerve 10 : 949-951
37. 37. Yunis EJ, Samaha FJ (1971) Inclusion body myositis. Lab Invest 25 : 240-248